Novel agents for chronic lymphocytic leukemia

Mei Wu; Akinleye, Akintunde; Xiongpeng Zhu
June 2013
Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1
Academic Journal
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.


Related Articles

  • Idelalisib approved for three blood cancers. Traynor, Kate // American Journal of Health-System Pharmacy;9/1/2014, Vol. 71 Issue 17, p1430 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of idelalisib oral tablets for blood cancer on July 23, 2014. Topics covered include the types of blood cancer indicated in the labeling for the drug, the approval made via the breakthrough therapy program of FDA...

  • Targeting Bruton's tyrosine kinase in B cell malignancies. Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P. // Nature Reviews Cancer;Apr2014, Vol. 14 Issue 4, p219 

    Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in...

  • Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Semichon, M; Merle-Béral, H; Lang, V; Bismuth, G // Leukemia (08876924);Nov97, Vol. 11 Issue 11, p1921 

    One characteristic of B cells that accumulate during chronic lymphocytic leukemia (CLL) is their highly heterogeneous functional responses to B cell receptor (BCR) stimulation. Leukemic B cells with very poor responses have defective rapid tyrosine phosphorylation of numerous substrates,...

  • Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Giovanni Carulli; Alessandra Stacchini; Alessandra Marini; Maria Matilde Ciriello; Alessandra Zucca; Elisa Cannizzo; Sabrina Aliberti; Anna Demurtas; Domenico Novero; Lara Calcagno; Tiziana Callegari; Mario Petrini // American Journal of Clinical Pathology;Aug2009, Vol. 132 Issue 2, p186 

    T-cell antigen expression can be observed in B-cell non-Hodgkin lymphoma (B-NHL). Although CD5 is expressed in B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma, the presence of other T-cell antigens is less common. This article reports a retrospective multicenter analysis in...

  • First-line therapy of advanced chronic lymphocytic leukemia. Wilhelm, M.; Tony, H.-P.; Rueckle-Lanz, H.; Wilms, K. // Leukemia (08876924);Apr97 Supplement 2, Vol. 11, pS14 

    There is general agreement that patients with advanced chronic lymphocytic leukemia (CLL) should be treated if they develop anemia or thrombocytopenia. The combination of chlorambucil (CLB) and prednisone is often used for first-line therapy of these patients, but compared to monotherapy with...

  • Purine analogs in the treatment of chronic lymphocytic leukemia. Pott, C.; Hiddemann, W. // Leukemia (08876924);Apr97 Supplement 2, Vol. 11, pS25 

    The purine analogs fludarabine (FAMP) and 2-chlorodeoxyadenosine (2-CDA) are highly active in chronic lymphocytic leukemia (CLL). In second-line therapy response rates are in the range of 30 to 60% and exceed 70% when applied to previously untreated patients. While FAMP in particular is thus...

  • Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Toze, C L; Shepherd, J D; Connors, J M; Voss, N J; Gascoyne, R D; Hogge, D E; Klingemann, H-G; Nantel, S H; Nevill, T J; Phillips, G L; Reece, D E; Sutherland, H J; Barnett, M J // Bone Marrow Transplantation;3/15/2000, Vol. 25 Issue 6, p605 

    Twenty-six patients with low-grade lymphoma (LGL) (n = 18) or chronic lymphocytic leukemia (CLL) (n = 8) received allogeneic BMTs between 1985 and 1998. Median age was 42 years, median interval from diagnosis to transplant 22 months and median number of prior treatments three. Twenty (77%) had...

  • Oral Fludarabine. Plosker, Greg L.; Figgitt, David P. // Drugs;2003, Vol. 63 Issue 21, p2317 

    â–´ Fludarabine is an antimetabolite antineoplastic agent used in the treatment of various haematological malignancies, particularly B-cell chronic lymphocytic leukaemia (CLL). â–´ An oral formulation of fludarabine has recently become available in the majority of European countries for...

  • Ibrutinib.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p157 

    The article presents a case study of a 67-year-old man who developed rash after receiving ibrutinib therapy for chronic lymphocytic leukaemia and deletion of chromosome.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics